Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Retained Earnings: 2015-2025

Historic Retained Earnings for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to -$1.6 billion.

  • Editas Medicine's Retained Earnings fell 14.04% to -$1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 billion, marking a year-over-year decrease of 14.04%. This contributed to the annual value of -$1.5 billion for FY2024, which is 19.25% down from last year.
  • As of Q3 2025, Editas Medicine's Retained Earnings stood at -$1.6 billion, which was down 1.43% from -$1.6 billion recorded in Q2 2025.
  • Editas Medicine's 5-year Retained Earnings high stood at -$721.9 million for Q1 2021, and its period low was -$1.6 billion during Q3 2025.
  • In the last 3 years, Editas Medicine's Retained Earnings had a median value of -$1.4 billion in 2024 and averaged -$1.4 billion.
  • Data for Editas Medicine's Retained Earnings shows a maximum YoY plummeted of 35.44% (in 2021) over the last 5 years.
  • Editas Medicine's Retained Earnings (Quarterly) stood at -$857.7 million in 2021, then dropped by 25.70% to -$1.1 billion in 2022, then fell by 14.21% to -$1.2 billion in 2023, then declined by 19.25% to -$1.5 billion in 2024, then fell by 14.04% to -$1.6 billion in 2025.
  • Its Retained Earnings was -$1.6 billion in Q3 2025, compared to -$1.6 billion in Q2 2025 and -$1.5 billion in Q1 2025.